Loading...
•
Sep 30, 2024
Eton Q3 2024 Earnings Report
Achieved positive GAAP net income from product revenue and reported 15th straight quarter of sequential growth in product revenue.
Key Takeaways
Eton Pharmaceuticals reported a strong third quarter with product sales reaching $9.8 million, a 40% increase year-over-year. The company achieved positive GAAP net income from product revenue for the first time. They also entered an agreement to acquire Increlex and had their NDA for ET-400 accepted by the FDA.
Delivered 15th straight quarter of sequential growth in product sales and reported positive GAAP net income.
Eton reported third quarter 2024 product sales of $9.8 million, representing 40% growth over the prior year period.
Entered into an asset purchase agreement to acquire Increlex® from Ipsen S.A.
New Drug Application (NDA) for ET-400 accepted by the U.S. Food and Drug Administration (FDA).
Revenue by Segment
Forward Guidance
2025 is shaping up to be a transformational year for Eton Pharmaceuticals with the upcoming closing of the Increlex acquisition and ET-400 PDUFA date approaching.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...